RICHMOND, Calif., Aug. 1, 2014 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO) a robotic exoskeleton company, today announced that CEO Nathan Harding will be interviewed live by host Kelly Evans on CNBC Network's Closing Bell. Any interested parties may tune in and listen live.
Date: Monday August 4, 2014
Start Time: 4:50 pm ET
Show: Closing Bell
Host: Kelly Evans
Live television stream: http://www.cnbc.com/live-tv/
Kelly Evans is co-anchor of CNBC's "Closing Bell." She joined the network in February 2012 as an on-air correspondent, reporting across CNBC's business day programming. Previously, Evans was co-anchor of CNBC's "Squawk on the Street" as well as co-anchor of CNBC's "Worldwide Exchange" based in London. Prior to CNBC, Evans was a reporter and columnist for The Wall Street Journal, penning the influential "Ahead of the Tape" column and writing for "Heard on the Street." She also hosted the daily "News Hub" program on WSJ.com and was a frequent guest on television and radio networks, including CNBC. Evans joined the Journal in 2007 as a reporter covering real estate and economics. Evans graduated magna cum laude with a bachelor's degree from Washington & Lee University in Lexington, Va., where she was a George Washington Honor Scholar, a four-time scholar-athlete, and inducted into the national leadership society, Omicron Delta Kappa.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at www.eksobionics.com
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's Current Report on Form 8-K/A filed on March 31, 2014 and the Company's latest Form 10-Q filed on May 13, 2014. The Company does not undertake to update these forward-looking statements.
CONTACT: Media Contact: Heidi Darling, Marketing Manager Phone: 415.302.4777 email@example.com Investor Contact: Lauren Glaser, Vice President Phone: 646.378.2972 firstname.lastname@example.orgSource:Ekso Bionics